These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 7861175

  • 1. Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride.
    Seeman P, Van Tol HH.
    J Neurochem; 1995 Mar; 64(3):1413-5. PubMed ID: 7861175
    [Abstract] [Full Text] [Related]

  • 2. D4 receptors and schizophrenia.
    Strange PG, Vile JM.
    J Neurochem; 1995 Nov; 65(5):2381-3. PubMed ID: 7595530
    [No Abstract] [Full Text] [Related]

  • 3. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
    Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W, Potkin S, Jones EG.
    Brain Res; 1997 Aug 08; 765(1):7-12. PubMed ID: 9310388
    [Abstract] [Full Text] [Related]

  • 4. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.
    Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY.
    Brain Res; 1995 May 29; 681(1-2):109-16. PubMed ID: 7552267
    [Abstract] [Full Text] [Related]

  • 5. Dopamine D4 receptors elevated in schizophrenia.
    Seeman P, Guan HC, Van Tol HH.
    Nature; 1993 Sep 30; 365(6445):441-5. PubMed ID: 8413587
    [Abstract] [Full Text] [Related]

  • 6. The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia.
    Marzella PL, Hill C, Keks N, Singh B, Copolov D.
    Biol Psychiatry; 1997 Oct 15; 42(8):648-54. PubMed ID: 9325557
    [Abstract] [Full Text] [Related]

  • 7. Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.
    Noda-Saita K, Matsumoto M, Hidaka K, Hatanaka K, Ohmori J, Okada M, Yamaguchi T.
    Biochem Biophys Res Commun; 1999 Feb 16; 255(2):367-70. PubMed ID: 10049714
    [Abstract] [Full Text] [Related]

  • 8. Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride.
    Seeman P, Guan HC, Van Tol HH.
    Eur J Pharmacol; 1995 Nov 14; 286(2):R3-5. PubMed ID: 8605946
    [Abstract] [Full Text] [Related]

  • 9. Are striatal dopamine D4 receptors increased in schizophrenia?
    Reynolds GP, Mason SL.
    J Neurochem; 1994 Oct 14; 63(4):1576-7. PubMed ID: 7931313
    [Abstract] [Full Text] [Related]

  • 10. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Seeman P, Guan HC, Van Tol HH, Niznik HB.
    Synapse; 1993 Aug 14; 14(4):247-53. PubMed ID: 8248849
    [Abstract] [Full Text] [Related]

  • 11. Brain sigma receptors labelled by [3H]nemonapride.
    Helmeste D, Tang SW, Fang H, Li M.
    Eur J Pharmacol; 1996 Apr 22; 301(1-3):R1-3. PubMed ID: 8773467
    [Abstract] [Full Text] [Related]

  • 12. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.
    Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE.
    J Neurosci; 1995 Mar 22; 15(3 Pt 2):2186-91. PubMed ID: 7891160
    [Abstract] [Full Text] [Related]

  • 13. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.
    Malmberg A, Jerning E, Mohell N.
    Eur J Pharmacol; 1996 May 06; 303(1-2):123-8. PubMed ID: 8804920
    [Abstract] [Full Text] [Related]

  • 14. [3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions.
    Vile JM, D'Souza UM, Strange PG.
    J Neurochem; 1995 Feb 06; 64(2):940-3. PubMed ID: 7830089
    [Abstract] [Full Text] [Related]

  • 15. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1.
    Primus RJ, Thurkauf A, Xu J, Yevich E, McInerney S, Shaw K, Tallman JF, Gallagher DW.
    J Pharmacol Exp Ther; 1997 Aug 06; 282(2):1020-7. PubMed ID: 9262371
    [Abstract] [Full Text] [Related]

  • 16. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
    Florijn WJ, Tarazi FI, Creese I.
    J Pharmacol Exp Ther; 1997 Feb 06; 280(2):561-9. PubMed ID: 9023264
    [Abstract] [Full Text] [Related]

  • 17. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.
    Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C.
    Proc Natl Acad Sci U S A; 1989 Dec 06; 86(24):10156-60. PubMed ID: 2574862
    [Abstract] [Full Text] [Related]

  • 18. Regional distribution of dopamine D4 receptors in rat forebrain.
    Tarazi FI, Kula NS, Baldessarini RJ.
    Neuroreport; 1997 Nov 10; 8(16):3423-6. PubMed ID: 9427299
    [Abstract] [Full Text] [Related]

  • 19. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects.
    Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA.
    Neuroreport; 1996 Aug 12; 7(12):1945-8. PubMed ID: 8905699
    [Abstract] [Full Text] [Related]

  • 20. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K, Tada S, Matsumoto M, Ohmori J, Tasaki Y, Nomura T, Usuda S, Yamaguchi T.
    Br J Pharmacol; 1996 Apr 12; 117(8):1625-32. PubMed ID: 8732269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.